Shizane's Wild World of BioTechs

[25 Kilos of Gold]

CTIX. The REAL DEAL. Awesome 10K report today. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and

read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

[Shizane]

ACST: The stock had a good day with a lot of volume. Shares traded were around 525K while the 10 day moving average is around 150K. The stock also reached a high of $1.00 before retracting to .957.

I am currently up around .50%.

Remember volume increases could me an increase in share price.

[Shizane]

AEZS: Had good volume again today. The 10 day moving volume is around 570K shares trade and today the volume was 1.2M shares traded, this was more than double the average volume.

The stock finished $0.01 lower. I am still up around 3.5%.

Last week it did a similar move when it reached the 1.25 area - heavy volume, increase in share price, then a slight retrace.

Remember volume increases could me an increase in share price.

[Shizane]

AEZS: Had a good appreciation in share price today. Stock went up around 4.7% today on late volume starting around 3PM. Volume ended at over 1.3M shares traded and the 10 day moving volume is around 550K shares traded.

I always look at an increase in share price with a significant increase in volume as a sign there could be more good things to come.

Currently I am up over 5% from my buy last friday.

Reply to:

PURCHASE: AEZS @ 1.26 in the Speculative Plays account.

Looking for possible information on the NDA for Macrilen as well a run up to the PDUFA during early November 2014.

Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results

[Shizane]

PURCHASE: AEZS @ 1.26 in the Speculative Plays account.

Looking for possible information on the NDA for Macrilen as well a run up to the PDUFA during early November 2014.

Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results

[Shizane]

PURCHASE: ACST @ .95 in the Speculative Plays account.

Expecting this to run up to the end of September 2014.

Top line results from Phase II "TRIFECTA" Trial

to evaluate the safety and efficacy of CaPre(R) in reducing triglyceride levels in patients with mild to severe hypertriglyceridemia

do at end of September 2014.

Acasti Completes Phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials

[Shizane]

SELL: 206 shares of POM from the Speculative Plays account for the proceeds of $5,564.24.



This money is the initial funding for the account. Remember this is a riskier account.

[Shizane]

Welcome to Shizane's Wild World of BioTechs.

On this board I will track my trading success and failures.

This board will be filled with helpful news on the Healthcare sector, as well as other useful information.

I will be posting buys and sells of stocks, mutual funds and ETFs associated to the Healthcare sector. Most of these will be in the BioTech subcategory.

These are not recommendations to buy or sell any stock that appears on this page.

I also reserve the right to buy or sell any stocks, mutual funds or ETFs at my sole discretion.

Thanks for looking at the board and if you have any questions or comments don't be afraid to post on the board or send a private message.